Welcome to our dedicated page for Trevena news (Ticker: TRVN), a resource for investors and traders seeking the latest updates and insights on Trevena stock.
About Trevena Inc.
Trevena Inc. (Nasdaq: TRVN) is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies targeting central nervous system (CNS) disorders. Leveraging cutting-edge research on G protein-coupled receptors (GPCRs), Trevena aims to address significant unmet medical needs by advancing novel mechanisms of action in pain management, epilepsy, and other CNS-related conditions. The company is headquartered in Chesterbrook, Pennsylvania, and operates within the highly specialized biopharmaceutical industry.
Core Focus and Product Pipeline
Trevena's expertise lies in its ability to develop therapies that provide differentiated clinical benefits. Their product pipeline reflects a commitment to innovation and patient-centric outcomes:
- OLINVYK® (oliceridine) injection: Trevena’s FDA-approved intravenous opioid analgesic for the management of acute pain in adults who require an opioid and for whom alternative treatments are inadequate. Designed with a unique mechanism of action, OLINVYK aims to reduce the risks commonly associated with traditional opioids.
- TRV045: An investigational S1P1 receptor modulator designed for the treatment of diabetic neuropathic pain and epilepsy. Preclinical studies suggest TRV045 offers sustained analgesic effects without causing receptor desensitization or lymphopenia, differentiating it from existing therapies.
- TRV250: A preclinical candidate targeting migraines with a novel approach to CNS pain processing.
- TRV734: A compound in development for the maintenance treatment of opioid use disorder, showcasing Trevena’s commitment to addressing the opioid crisis.
In addition to its advanced pipeline, Trevena maintains an early-stage portfolio of drug discovery programs focused on GPCR-targeted therapies, demonstrating its long-term commitment to innovation.
Scientific and Competitive Edge
Trevena’s research is underpinned by Nobel Prize-winning discoveries in GPCR biology, positioning the company as a leader in leveraging biased ligand signaling to develop safer and more effective therapies. Their focus on CNS disorders allows them to tackle complex medical challenges with precision. By emphasizing novel mechanisms of action, Trevena differentiates itself from competitors in the biopharmaceutical space.
Key advantages include:
- Differentiated Mechanisms: TRV045’s unique ability to provide sustained S1P1 receptor agonism without desensitization offers a promising alternative to traditional modulators like fingolimod.
- Patient-Centric Outcomes: Trevena’s therapies aim to improve patient safety and efficacy profiles, addressing critical gaps in current treatment options.
- Regulatory Expertise: The successful FDA approval of OLINVYK demonstrates Trevena’s capability to navigate the complex regulatory landscape.
Market Position and Challenges
Trevena operates in a competitive market, contending with other biopharmaceutical companies focused on CNS disorders and pain management. Challenges include the high costs and risks associated with clinical trials, regulatory approvals, and commercialization. However, their focus on innovative, differentiated products and their ability to address unmet needs provide a strong foundation for growth and market relevance.
Conclusion
With a robust pipeline, a commitment to innovation, and a focus on addressing critical gaps in CNS disorder treatments, Trevena Inc. stands as a notable player in the biopharmaceutical industry. Their emphasis on novel mechanisms of action and patient-centric outcomes highlights their potential to make significant contributions to healthcare and improve the lives of patients worldwide.
Trevena, Inc. (Nasdaq: TRVN) announced that Wake Forest Baptist Health Medical Center will participate in the VOLITION study to assess the impact of OLINVYK (oliceridine) on postoperative respiratory, gastrointestinal, and cognitive outcomes. The study, led by Cleveland Clinic, will enroll approximately 200 adults and is expected to begin patient enrollment in Q3 2021. Mark A. Demitrack, M.D., stated that the results could enhance understanding of OLINVYK's clinical value, aiming to address significant clinical needs related to pain management.
Trevena, Inc. (TRVN) reported a net loss of $14 million for Q2 2021, up from $6.2 million the previous year. The company has achieved 35 formulary approvals for OLINVYK, with a goal of 100 by year-end. Ongoing studies for OLINVYK and TRV027 aim to enhance understanding of their efficacy in various medical conditions. Cash reserves stand at $91 million, sufficient to cover operational expenses through Q4 2022. Trevena's stock has been added to Russell 2000, Russell 3000, and Russell Microcap indexes, enhancing its visibility among investors.
Trevena, Inc. (Nasdaq: TRVN) announced an exploratory analysis revealing that patients treated with OLINVYK (oliceridine) are approximately 50% less likely to experience adverse events compared to those treated with IV morphine at equal analgesic levels. Conducted using data from the OLINVYK Phase 3 program, the analysis showed a significant odds ratio indicating lower treatment-emergent adverse events for OLINVYK, suggesting a favorable benefit-risk profile for post-operative pain management. The publication can be found in the relevant medical journal and was authored by Dr. Gregory B. Hammer.
Trevena, Inc. (Nasdaq: TRVN) will announce its second quarter financial results on August 12, 2021, before the market opens. A conference call will follow at 8:00 a.m. ET, featuring key executives including President Carrie Bourdow and CFO Barry Shin. Trevena focuses on developing novel medicines for central nervous system disorders, with one approved product, OLINVYK® (oliceridine) injection, and a pipeline including four investigational drug candidates targeting migraine and opioid use disorder.
Trevena, Inc. (Nasdaq: TRVN) has initiated patient enrollment for the ACTIV-4 Host Tissue trial, focusing on COVID-19 treatments. TRV027, an innovative AT1 receptor selective agonist, aims to combat the damaging effects of COVID-19 on the lungs and blood clotting. The trial will include around 1,600 patients at over 50 sites across the U.S. TRV027 has previously shown promise in clinical settings with a favorable safety profile. The study's goal is to evaluate the effectiveness of various agents, including TRV027, in preventing severe outcomes in hospitalized COVID-19 patients.
Trevena, Inc. (Nasdaq: TRVN) announced a published health economic model for its drug OLINVYK (oliceridine) in the Journal of Comparative Effectiveness Research. The model shows significant cost savings for hospitals using OLINVYK over IV morphine for postoperative pain management. The analysis indicates a reduction in total care costs per 1,000 patients due to fewer adverse effects noted in Phase 3 trials. This publication is expected to aid formulary reviews, supporting the drug's utilization in acute pain management.
Trevena, Inc. (TRVN) has partnered with Nhwa to begin a Phase 3 trial for OLINVYK (oliceridine) injection in China, targeting acute pain management. The trial, which has enrolled its first patient, aims to include around 160 participants following abdominal surgery. Trevena expects to gain 10% royalty on net sales and anticipates receiving approval and commercialization milestones. The study's primary endpoint focuses on pain relief efficacy, with safety assessed via various adverse events. Successful completion may lead to regulatory filing for OLINVYK in China.
Trevena, Inc. (Nasdaq: TRVN) has announced a new study evaluating the respiratory effects of OLINVYK in elderly and obese patients. The Phase 1 trial, led by Dr. Albert Dahan, will compare OLINVYK with IV morphine using an innovative clinical utility function analysis. Enrollment is expected in Q3 2021, aiming for topline data by YE 2021. This study is part of Trevena’s strategy to enhance evidence for OLINVYK’s clinical profile and assess its therapeutic potential in managing acute pain.
Trevena, Inc. (Nasdaq: TRVN) announced its addition to the Russell 2000®, Russell 3000®, and Russell Microcap® Indexes, effective June 28, 2021. This inclusion signifies a positive recognition for Trevena, reflecting the value from the launch of its product OLINVYK and progress in its pipeline. The move is expected to enhance the company's visibility, broaden its shareholder base, and improve stock liquidity, according to President and CEO Carrie Bourdow. Russell indexes manage approximately $9 trillion in assets.
Trevena, Inc. (Nasdaq: TRVN) announced that the National Institute on Drug Abuse (NIDA) has resumed patient recruitment for the proof-of-concept study of TRV734, a novel oral treatment for opioid use disorder (OUD). The study, paused in March 2020 due to COVID-19, aims to evaluate TRV734's efficacy in reducing withdrawal symptoms. The clinical trial will involve approximately 50 patients and assess both safety and tolerability. TRV734 targets the mu-opioid receptor and shows promise in preclinical studies, potentially offering a better-tolerated option than existing treatments.
FAQ
What is the current stock price of Trevena (TRVN)?
What is the market cap of Trevena (TRVN)?
What does Trevena Inc. specialize in?
What is OLINVYK?
What is TRV045 and how is it unique?
What makes Trevena's approach to drug development unique?
What are the main challenges Trevena faces?
Does Trevena have any products currently approved by the FDA?
What is Trevena's competitive advantage?
What is the focus of Trevena's early-stage research programs?
